Oculis Holding AG (NASDAQ:OCS) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Oculis Holding AG's stock has a consensus rating of "Moderate Buy" from five analysts, with one sell recommendation and four buy recommendations, and an average price target of $35.75.
• In its latest earnings report, Oculis reported an EPS of ($0.59), missing expectations, while revenue was $0.25 million, surpassing predictions.
• Institutional investors have increased their stakes in Oculis, with notable purchases by firms like Kestra Private Wealth Services and Bank of America Corp DE.

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $35.75.

Several research firms have weighed in on OCS. Wall Street Zen cut Oculis from a "hold" rating to a "sell" rating in a report on Sunday, September 21st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oculis in a report on Saturday, September 27th. HC Wainwright raised their price target on Oculis from $32.00 to $33.00 and gave the company a "buy" rating in a report on Friday, August 22nd. Finally, Needham & Company LLC began coverage on Oculis in a report on Wednesday, August 27th. They issued a "buy" rating and a $36.00 price target on the stock.

Oculis Stock Up 0.6%

OCS traded up $0.10 during trading on Friday, reaching $17.57. 20,345 shares of the company were exchanged, compared to its average volume of 23,018. The company's 50-day moving average is $17.50 and its two-hundred day moving average is $18.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.55 and a current ratio of 4.55. Oculis has a 12-month low of $12.48 and a 12-month high of $23.08.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). The company had revenue of $0.25 million for the quarter, compared to analysts' expectations of $0.14 million. Oculis had a negative return on equity of 90.31% and a negative net margin of 13,958.12%. On average, research analysts predict that Oculis will post -2.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Oculis

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Kestra Private Wealth Services LLC bought a new stake in shares of Oculis in the 1st quarter worth approximately $234,000. Bosun Asset Management LLC bought a new stake in shares of Oculis in the 2nd quarter worth approximately $378,000. Marshall Wace LLP bought a new stake in shares of Oculis in the 2nd quarter worth approximately $393,000. Bank of America Corp DE grew its position in shares of Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after buying an additional 10,667 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock worth $571,000 after buying an additional 6,384 shares during the last quarter. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.